Elepsia XR (Levetiracetam) Patent Expiration, LOE Window & CMS Spending
Elepsia XR (Levetiracetam) by Tripoint Therap: FDA Orange Book LOE 2027-10-31, 10 AB generics, $128K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Tripoint Therap |
| FDA Application & Pathway | N204417 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2027-10-31 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 10 |
| 2024 CMS Total Public Spend | $128K |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $128K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |